In April 2025, Vir Biotechnology Inc. announced a phase 1b/2 platform study framework to evaluate the safety and efficacy of ...

The U.S. capacity to battle hepatitis B and C has been leveled a devastating blow with the recent closure of the CDC’s ...

Catching HBV early can make a world of difference. Medical professionals typically use blood tests that check for signs of ...

Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases. The company is dedicated to educating ...

The following is a summary of “Chronic hepatitis B virus infection increases the risk of kidney disease while antiviral ...

Currently, there is no feline vaccine for the hepatitis B virus, and the hepatitis B vaccine for humans is highly toxic to ...

Washington [US], April 10 (ANI): Researchers found out how chronic infection with the hepatitis B virus (HBV ... and analyzed their effects in a mouse model of HBV. After introducing TSCMs ...

The hepatitis B virus can cause a mild, temporary (acute) illness or a serious, lifelong (chronic) disease. An estimated 880,000 to 1.89 million people in the United States have chronic hepatitis ...

Scientists from the Institut Pasteur, in collaboration with Kumamoto University in Japan, have assessed a new rapid diagnostic test to identify pregnant women at elevated risk of transmitting ...

The hepatitis B virus infects liver cells and is not to be confused with other types of hepatitis viruses, including the better known hepatitis A and C. The virus is spread by bodily fluids ...

Health care workers are at higher risk of hepatitis B infection due to occupational exposure to blood and body fluids.